Device Trial Radar · NCT07888582
Effectiveness and Safety of the RIGHTEST™ CGM System for Blood Glucose Management in Persons With Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 9, 2024
Primary completion
Dec 19, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Bionime CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is expected to enroll 50 confirmed cases of type 1 or type 2 diabetes. All eligible subjects must wear a continuous glucose monitoring system on both the left and right upper arms for a maximum of 15 days (360 hours) and adhere to the clinical visit protocol. After enrollment, all subjects will be randomly assigned to either Group A or Group B to determine the time points for clinical visits. All subjects will have venous blood drawn on days 1, days 5 (±1), 10 (±1), and 15 (-1) post-wearing. All subjects will remove all devices on day 15 (-1) based on system prompts and undergo a telephone follow-up on day 4 (±3) thereafter. This clinical trial does not involve long-term follow-up. During the trial, the blood glucose values measured by the "continuous glucose monitoring system" worn by the subjects will be analyzed against the YSI venous blood glucose values measured at the medical institution on days 1, 5 (±1), 10 (±1), and 15 (-1) as control reference values. This analysis aims to evaluate the accuracy, repeatability, stability, high and low blood glucose event alerts, and safety of the continuous glucose monitoring system. Additionally, fingertip blood glucose measurements taken by subjects during home use will be collected to assess the operational feasibility of the continuous glucose monitoring system in a home setting.
Conditions
- Diabetes Mellitus
Interventions
RIGHTEST Continuous Glucose Monitoring SystemDevice
Adults with type 1 or type 2 diabetes mellitus wore two RIGHTEST (HM510) CGM sensors, one on each upper arm, for up to 15 days. Device accuracy was evaluated against venous blood glucose measurements during four in-clinic frequent blood sampling visits.
Primary outcomes
What the sponsor says the trial is designed to measure.
- accuracyTime frame: 15 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm
Ulm, Baden-Wurttemberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.